Get the Stockscreener App
1.04
4.00%
0.04
Barinthus Biotherapeutics Plc Adr stock is traded at $1.04, with a volume of 32,974.
It is up +4.00% in the last 24 hours and down -9.57% over the past month.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
See More
Previous Close:
$1.00
Open:
$1.01
24h Volume:
32,974
Relative Volume:
0.61
Market Cap:
$40.23M
Revenue:
$13.42M
Net Income/Loss:
$-73.35M
P/E Ratio:
-0.5417
EPS:
-1.92
Net Cash Flow:
$-56.34M
1W Performance:
-5.05%
1M Performance:
-9.57%
6M Performance:
-25.18%
1Y Performance:
-60.90%
1-Day Range:
$1.005
$1.10
1-Week Range:
$0.9599
$1.19
52-Week Range:
$0.8008
$4.1591
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Name
Barinthus Biotherapeutics Plc Adr
Sector
Industry
Phone
44 (0) 1865 818808
Address
UNIT 6-10, ZEUS BUILDING, DIDCOT
Compare BRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
1.04 | 40.23M | 13.42M | -73.35M | -56.34M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.66 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.67 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.27 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.20 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | Morgan Stanley | Overweight |
| May-25-21 | Initiated | William Blair | Outperform |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News
Dollar General Corp (DG) Shares Up Despite Recent Market Volatility - The News Heater
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why - MSN
Exclusive-Mexico's Pemex, billionaire Slim renegotiate deepwater gas project - Yahoo Finance
RBC raises Reckitt Benckiser stock target to £57.00, keeps outperform - MSN
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Barinthus Bio shifts focus, cuts workforce to extend cash runway - Investing.com
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):